Recently, Zhang Qian, assistant judge of the Beijing Intellectual Property Court, attended the online conference “Judicial Protection of Intellectual Property Rights on April 26, 2022” organized by the Beijing Intellectual Property Judicial Protection Research Society, and gave a symposium on legal publicity to relevant practitioners under the theme “Hot spots and difficulties in trademark protection practices of enterprises——Analysis of Typical Cases about Trademark Authorization and Determination.”
China’s State Administration for Market Regulation Releases Legislative Work Plan for 2022
On April 27, 2022, China’s State Administration for Market Regulation released the State Administration for Market Regulation on Printing and Distributing Notice of Legislative Work Plan for 2022 (市场监管总局关于印发2022年立法工作计划的通知), which includes several intellectual property laws and administrative regulations among the 69 projects identified. IP-Related laws, regulations and rules, etc. are highlighted in the tables below. Note that the Detailed Implementation Rules of the Patent Law are not listed below but are mentioned in the text of the plan. Hopefully, the …
China’s Ministry of Public Security Announces Ten Typical Cases of Combating Intellectual Property Infringement Crimes
According to 中国警察网, on April 21, 2022, China’s Ministry of Public Security announced “Ten Typical Cases of Combating Intellectual Property Infringement Crimes” (公安部公布打击侵犯知识产权犯罪十起典型案例). Crimes includes selling counterfeit athletic shoes, copyright infringement of various movies including the Chinese blockbuster The Battle at Lake Changjin about the Korean war as viewed from the Chinese side, counterfeit cosmetics, and fake corn seeds, etc.
China’s National Intellectual Property Administration Rules in First Batch of Patent Linkage Cases
On April 26, 2022, the China National Intellectual Property Administration (CNIPA) announced that is concluded the first batch of patent linkage cases related to “Oxycodone Hydrochloride Sustained-Release Tablets” from Purdue Pharmaceuticals. China’s patent linkage system prevents marketing authorization for a generic prior to the expiration of the patent term on the branded equivalent unless the Beijing IP Court or the China National Intellectual Property Administration (CNIPA) rules that the generic does not fall within the scope of the relevant patent rights …